You searched for "dystrophy"
A week in the world of ophthalmology: A reflective journey at New Cross Hospital
3 October 2024
| Nikhil Sharma
|
EYE - General
Embarking on a taster week in ophthalmology at New Cross Hospital was a decision fuelled by the desire to delve into the intricacies of this unique specialty, which blends surgical and medical traits. For foundation doctors, a taster week is...
Inherited retinal disorders now the leading cause of blindness
1 April 2014
| Thomas O'Neill
|
EYE - Vitreo-Retinal
The recent paper in BMJ Open, from the UCL Institute of Ophthalmology, ‘A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010’ concludes that inherited retinal disorders (IRD) such...
Macular atrophy and choriocapillaris nonperfusion
1 April 2019
| Saruban Pasu
|
EYE - Vitreo-Retinal
This Japanese study compared the choriocapillaris (CC) nonperfusion area as measured on OCTA with areas of macular atrophy (MA) measured by fundus autofluoresence (FAF). A total of 44 eyes were assessed (31 were treated with anti-VEGF alone and 13 had...
Detection of SO tendon abnormality versus atrophy
This study aimed to evaluate patterns of binocular misalignment in primary gaze, lateral and vertical gaze, and head tilt in patients showing head-tilt dependent hypertropia associated with discontinued superior oblique (SO) tendon but without SO muscle atrophy, versus patients with...In conversation with Professor Usha Chakravarthy (2018)
1 March 2019
|
EYE - Vitreo-Retinal, EYE - General
Professor Chakravarthy popped by the Eye News stand at the 2018 Royal College of Ophthalmologists Annual Congress after her excellent Bowman Lecture. She gave us a summary of her presentation, which looked at how our understanding of AMD has changed...
Atrophy and anti-VEGF
1 August 2019
| Saruban Pasu
|
EYE - Vitreo-Retinal
The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...
Progression of macular atrophy on long-term anti-VEGF therapy for AMD
3 October 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Anti-VEGF therapy, Long term, Macular atrophy, neovascular age-related macular degeneration
This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...
The natural history of treatment naïve choroidal neovascularisation (CNV) in geographic atrophy
1 February 2018
| Efrosini Papagiannuli
|
EYE - Vitreo-Retinal
The aim of this retrospective study is to assess the characteristics and natural history of quiescent CNV in geographic atrophy (GA) utilising multi-modal imaging. Case notes were reviewed of patients diagnosed with geographic atrophy between January 2010 and December 2016...
Nano-ophthalmology paves a new path in the future of eyecare
1 December 2022
| Stylianos Mastronikolis, Jayasis Bandyopadhyay
|
EYE - General
Introduction The treatments of ocular conditions in the field of ophthalmology varies from topical to surgical procedures. The field of nanotechnology is one of the fast-growing fields of medicine, which plays an important role in turning the impossibilities of the...
Saving sight and changing lives: working with Syrian refugees in Jordan
Two ophthalmologists from the Emory Eye Center share their three-year experience of treating refugees in the camps in Jordan. Jordan currently hosts an estimated 1.4 million Syrian people who have fled the war in their home country. Cataract & Cornea...
Progression of myopic maculopathy after treatment
1 October 2014
| Sofia Rokerya
|
EYE - Vitreo-Retinal
The authors report on a retrospective study carried out to evaluate long-term progression of myopic maculopathy and functional outcome in eyes treated for myopic choroidal neovascularisation (CNV) and in eyes without CNV. Fifty-four myopic eyes of 30 patients were included...
